CeriBell, Inc. (NASDAQ:CBLL) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of CeriBell, Inc. (NASDAQ:CBLL) have been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $22.20.

Several equities analysts recently weighed in on CBLL shares. Canaccord Genuity Group cut their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 29th.

CeriBell Trading Down 0.4%

Shares of CBLL traded down $0.08 during trading hours on Friday, hitting $19.56. 197,196 shares of the stock traded hands, compared to its average volume of 364,622. The business has a fifty day moving average of $18.67 and a 200-day moving average of $19.65. The firm has a market capitalization of $742.17 million, a PE ratio of -12.00 and a beta of 0.77. CeriBell has a 1-year low of $10.85 and a 1-year high of $24.33. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The firm had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. Analysts expect that CeriBell will post -1.69 EPS for the current year.

Insiders Place Their Bets

In other CeriBell news, major shareholder Tpg Gp A, Llc sold 202,368 shares of the stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $20.12, for a total value of $4,071,644.16. Following the transaction, the insider owned 3,765,054 shares of the company’s stock, valued at approximately $75,752,886.48. This represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CTO Raymond Woo sold 1,966 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $18.00, for a total value of $35,388.00. Following the completion of the sale, the chief technology officer directly owned 195,682 shares of the company’s stock, valued at approximately $3,522,276. This trade represents a 0.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 350,789 shares of company stock valued at $6,946,191 in the last ninety days. 20.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CeriBell

Several institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its stake in CeriBell by 6,424.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after buying an additional 374,179 shares during the period. Rhumbline Advisers increased its holdings in shares of CeriBell by 109.9% in the second quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock worth $614,000 after acquiring an additional 17,177 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of CeriBell by 148.6% during the second quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after purchasing an additional 5,200 shares during the period. Quantbot Technologies LP lifted its holdings in shares of CeriBell by 70.3% during the 2nd quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock valued at $290,000 after purchasing an additional 6,401 shares in the last quarter. Finally, Invesco Ltd. acquired a new position in shares of CeriBell in the 2nd quarter valued at approximately $197,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.